COVIGEN project, needle-free SARS-CoV-2 Recombinant DNA vaccine

To date, over 31.2 million COVID-19 cases and 950 000 deaths, from the Coronavirus disease (COVID-19), have been reported around the world, including Thailand, to WHO.
From 14 through 20 September, there were almost 2 million new cases of COVID-19, which represents a 6% increase compared to the previous week, and the highest number of reported cases in a single week since the beginning of the epidemic. During the same period, there was a 10% decrease in the number of deaths, with 36 764 deaths reported in the past seven days. (https://covid19.who.int/)

The pandemic of new COVID-19 has led to the race in the development of SARS-CoV-2 vaccines through international collaborations among academics, research institutes and private sectors with 300 vaccine projects using technologies such as DNA, mRNA, or recombinant vaccines.
The future control of SARS-CoV-2 depends on the availability of one or more reliable and immunogenic vaccines. National and international initiatives are being implemented on an unprecedented scale to develop safe and effective vaccines.

Our “COVIGEN project” was selected by the Medical Research Future Fund (MRFF) to be evaluated for a clinical trial in Australia. (source: Australia's first COVID-19 vaccine study to begin)

Our manufacturing facilities are already equipped for production of recombinant vaccines which can be also used for manufacturing vaccines against COVID-19 at medium or large scale when product development is completed.

For more information about our commitment to develop a vaccine against COVID-19, please contact us at covigen@bionet-asia.com